These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32158975)

  • 41. Urinary Biomarkers in Women with Refractory Urgency Urinary Incontinence Randomized to Sacral Neuromodulation versus OnabotulinumtoxinA Compared to Controls.
    Richter HE; Moalli P; Amundsen CL; Malykhina AP; Wallace D; Rogers R; Myers D; Paraiso M; Albo M; Shi H; Nolen T; Meikle S; Word RA;
    J Urol; 2017 Jun; 197(6):1487-1495. PubMed ID: 28089729
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcomes of Sacral Nerve Stimulation for Treatment of Refractory Overactive Bladder Among Octogenarians.
    Greenberg DR; Syan R; Young-Lin N; Comiter CV; Enemchukwu E
    Neuromodulation; 2019 Aug; 22(6):738-744. PubMed ID: 31215713
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Women Undergoing Third Line Overactive Bladder Treatment Demonstrate Elevated Thermal Temporal Summation.
    Reynolds WS; Kowalik C; Cohn J; Kaufman M; Wein A; Dmochowski R; Bruehl S
    J Urol; 2018 Oct; 200(4):856-861. PubMed ID: 29746857
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sacral nerve stimulation reduces elevated urinary nerve growth factor levels in women with symptomatic detrusor overactivity.
    Shalom DF; Pillalamarri N; Xue X; Kohn N; Lind LR; Winkler HA; Metz CN
    Am J Obstet Gynecol; 2014 Nov; 211(5):561.e1-5. PubMed ID: 25019486
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of Urinary Urgency Incontinence Using a Rechargeable SNM System: 6-Month Results of the ARTISAN-SNM Study.
    McCrery R; Lane F; Benson K; Taylor C; Padron O; Blok B; De Wachter S; Pezzella A; Gruenenfelder J; Pakzad M; Perrouin-Verbe MA; Le Normand L; Van Kerrebroeck P; Mangel J; Peters K; Kennelly M; Shapiro A; Lee U; Comiter C; Mueller M; Goldman HB
    J Urol; 2020 Jan; 203(1):185-192. PubMed ID: 31347955
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Patients with Sacral Neuromodulation: What Are the Factors Affecting Their Therapy Satisfaction?
    Banakhar M; Hassouna M
    Urol Int; 2019; 103(4):450-453. PubMed ID: 31574517
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Sacral neuromodulation for refractory overactive bladder].
    van Ophoven A
    Urologe A; 2018 Nov; 57(11):1375-1388. PubMed ID: 30310935
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Trends and Clinical Practice Patterns of Sacral Neuromodulation for Overactive Bladder.
    Elterman DS; Chughtai B; Vertosick E; Thomas D; Eastham J; Sandhu J
    Female Pelvic Med Reconstr Surg; 2018; 24(4):264-266. PubMed ID: 28658001
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Update on Implantable PTNS Devices.
    Vollstedt A; Gilleran J
    Curr Urol Rep; 2020 May; 21(7):28. PubMed ID: 32462381
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Results of sacral posterior neuromodulation on voiding disorders and impact on sexuality based on a single-center study].
    Ferhi K; Miaadi N; Tanneau Y; Leroi AM; Sibert L; Grise P
    Prog Urol; 2008 Mar; 18(3):160-6. PubMed ID: 18472068
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overactive Bladder.
    White N; Iglesia CB
    Obstet Gynecol Clin North Am; 2016 Mar; 43(1):59-68. PubMed ID: 26880508
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patient preferences for treating refractory overactive bladder in the UK.
    Hashim H; Beusterien K; Bridges JF; Amos K; Cardozo L
    Int Urol Nephrol; 2015 Oct; 47(10):1619-27. PubMed ID: 26347077
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost profiles and budget impact of rechargeable versus non-rechargeable sacral neuromodulation devices in the treatment of overactive bladder syndrome.
    Noblett KL; Dmochowski RR; Vasavada SP; Garner AM; Liu S; Pietzsch JB
    Neurourol Urodyn; 2017 Mar; 36(3):727-733. PubMed ID: 27062384
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improvements in Self-Reported Depression Following Treatment of Fecal Incontinence with Sacral Neuromodulation.
    Gevelinger MM; Jaworski EM; Speranza JR; Sanderson DJ
    Neuromodulation; 2020 Dec; 23(8):1158-1163. PubMed ID: 32803836
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical outcomes of sacral neuromodulation in patients with neurologic conditions.
    Peters KM; Kandagatla P; Killinger KA; Wolfert C; Boura JA
    Urology; 2013 Apr; 81(4):738-43. PubMed ID: 23537757
    [TBL] [Abstract][Full Text] [Related]  

  • 56. What uro-gynecologists should know about sacral neuromodulation (SNM) for the treatment of refractory overactive bladder.
    Oelke M; Addali M; Reisenauer C
    Arch Gynecol Obstet; 2019 May; 299(5):1243-1252. PubMed ID: 30941558
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Motor Response Matters: Optimizing Lead Placement Improves Sacral Neuromodulation Outcomes.
    Pizarro-Berdichevsky J; Gill BC; Clifton M; Okafor HT; Faris AE; Vasavada SP; Goldman HB
    J Urol; 2018 Apr; 199(4):1032-1036. PubMed ID: 29154850
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Detrusor overactivity does not predict outcome of sacral neuromodulation test stimulation.
    South MM; Romero AA; Jamison MG; Webster GD; Amundsen CL
    Int Urogynecol J Pelvic Floor Dysfunct; 2007 Dec; 18(12):1395-8. PubMed ID: 17364132
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: A retrospective single-institution study.
    Kaaki B; Gupta D
    PLoS One; 2020; 15(7):e0235961. PubMed ID: 32645082
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of sacral neuromodulation in modern urogynaecology practice: a review of recent literature.
    Tahseen S
    Int Urogynecol J; 2018 Aug; 29(8):1081-1091. PubMed ID: 29302716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.